Enzon Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 73   

Articles published

ENZN 1.09 -0.02 (-1.80%)
price chart
Enzon Pharmaceuticals Inc (ENZN): Warning! Enzon Pharmaceuticals Is ...
Finance profile for the company! Right off the bat, that doesn't give us a lot of confidence, now does it? Enzon Pharmaceuticals (NASDAQ:ENZN) used to be a research stage biotech firm, focusing on a technology known as PEGylation. PEGylation was used ...
Enzon Pharmaceuticals Inc Stock Upgraded (ENZN)
Compared to other companies in the Biotechnology industry and the overall market, ENZON PHARMACEUTICALS INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
Update: Enzon Pharmaceuticals, Inc. Short Interest Grows by 20.3%
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) has witnessed a colossal rise of 20.3% or 18,868 shares in its short figure.
Share Price of Enzon Pharmaceuticals, Inc. Drops by -4.55%  Markets Bureau
Legendary Investor Icahn Still Slugging Away With Enzon Pharma
Carl C. Icahn has been the principal beneficial shareholder of Icahn Enterprises L.P. (NASDAQ:IEP) and has served as Chairman of the board, a director, and an owner of the company's general partner since 1990. Mr. Icahn heads the investment ...
Related articles »  
Enzon Pharmaceuticals, Inc. (ENZN): Are Hedge Funds Right About This Stock?
Is Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) a buy, sell, or hold? The best stock pickers are taking a bearish view.
Receptos Inc, Enzon Pharmaceuticals Inc Soar Midday
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) jumped +18.21% and continues on what has been a solid month-long run, its price up +21.73% since May 12th. Carl Icahn has maintained a 5.9-million-share position in the biotech firm across several quarters.
Enzon Pharmaceuticals sells Indy drug plant; 100 local jobs safe
Orphan drugs, as they're known in the pharmaceutical industry, treat diseases that afflict fewer than 200,000 patients in the United States.
Related articles »  
Enzon Pharmaceuticals Inc. Files SEC Form SC 13G, Statement of Acquisition of ...
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Enzon Pharmaceuticals, Inc. (ENZN): Insiders Aren't Crazy About It
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) was in 15 hedge funds' portfolio at the end of the first quarter of 2013.
Enzon Pharmaceuticals Inc Short Interest Climbs by 81.4%
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) reported a rise of 81.4% or 41,627 shares in its short interest. The short figure came in at 0.2% of the total floats.